Results 71 to 80 of about 1,034,952 (285)
Background Peritoneal metastasis (PM) develop in more than 50 % of gastric cancer (GC) patients. Median survival without treatment is not more than 3–7 months, and 8–12 months after modern combination chemotherapy.
V. Khomyakov+6 more
semanticscholar +1 more source
This study develops TMEclassifier, a machine‐learning tool that classifies cancers into three distinct subtypes—Immune exclusive (IE), immune suppressive (IS), and immune activated (IA)—which exhibit significant heterogeneity and necessitate customized therapeutic strategies.
Dongqiang Zeng+27 more
wiley +1 more source
Adapting tumor interstitial fluid pressure for intraperitoneal chemotherapy [PDF]
C
Ceelen, Wim+5 more
core +1 more source
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for primary peritoneal malignancies or peritoneal spread of malignant neoplasm is being done at many centres worldwide.
S. Solanki+22 more
semanticscholar +1 more source
This review compares clinical outcomes, translational progress, and global funding trends across cancer phototherapies—photodynamic, photothermal, and photoimmunotherapy—and conventional immunotherapy. It highlights differences in treatment efficacy, clinical trial status, financial investment, and regulatory challenges, providing a comprehensive ...
Deepak S. Chauhan+6 more
wiley +1 more source
Molecular mechanism study of self‐assembled M2pep‐Cs NPs/Plerixafor nanoparticles in targeting MΦ reprogramming by regulating the CXCL12–CXCR4 signaling pathway to enhance immune recognition and clearance of GC (Created by BioRender). Abstract Gastric carcinoma (GC) remains a major global health challenge, requiring novel therapeutic approaches.
Qianqian Cao+9 more
wiley +1 more source
Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer
Despite its widespread use, until recently, there was no randomized evidence for hyperthermic intraperitoneal chemotherapy (HIPEC) versus surgery without HIPEC for ovarian cancer.
I. Vergote, P. Harter, L. Chiva
semanticscholar +1 more source
Microsatellite‐stable (MSS) colorectal cancer (CRC) resists immunotherapy. PRMT5 inhibition enhances CPT‐11 sensitivity, inducing a PMS2‐deficient‐like state and cytosolic dsDNA release, which activates the cGAS‐STING pathway to promote anti‐tumor immunity. However, this combination therapy upregulates TIGIT expression on CD8+ T cells, and the addition
Jiang Zhu+10 more
wiley +1 more source
The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapy. [PDF]
The aim of the present study was to determine the usefulness of a patient-derived orthotopic xenograft (PDOX) nude-mouse model of a doxorubicin-resistant metastatic Ewing's sarcoma, with a unique combination of a FUS-ERG fusion and CDKN2A deletion, to ...
Bouvet, Michael+20 more
core +1 more source